NASDAQ$SHC
Sotera Health Company · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Sotera Health reported Q1 2025 total net revenues of $254.5M with a net loss of $13.3M and diluted EPS of $(0.05).
Total net revenues grew to $254.5 million as Sterigenics and Nelson Labs volumes increased. The net loss was $13.3 million, or $0.05 per diluted share, including a $30.9 million Illinois ethylene oxide litigation settlement charge.
- Q1 total net revenues $254.5M (+3% YoY).
- Net loss $13.3M; diluted EPS $(0.05).
- Illinois EO litigation settlement charge of $30.9M in the quarter.
- Nordion isotope revenue grew 36% year over year.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$255M
Revenue by segment
Sotera Health · $263M total across 3 segments · Q3 2023
- Sterigenics$168M+6.7%64.0%
- Nelson Labs$54.7M-2.1%20.8%
- Nordion$40.1M+14.3%15.2%
Forward guidance
Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.
Tailwinds
- Headline results and segment trends anchor the quarter.
- Liquidity and balance-sheet capacity support operations.
- Strategic initiatives outlined in MD&A.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items affect year-over-year comparability.
- Execution risk on growth or restructuring plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro